NCT04571463 is a clinical trial in Fetal Alcohol Spectrum Disorders, sponsored by Hanna Kahila.

Who is sponsoring NCT04571463?

NCT04571463 is sponsored by Hanna Kahila.

What condition does NCT04571463 study?

NCT04571463 studies Fetal Alcohol Spectrum Disorders.

Is NCT04571463 still recruiting?

NCT04571463 is currently completed. Last updated 28 November 2022.

Last reviewed 2022-11-28 · How we verify

NCT04571463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ethyl Glucuronide in Urine Samples of Pregnant Women Within the HUS ja PHHYKY Area

Completed Last updated 28 November 2022

What this trial tests

trial in Fetal Alcohol Spectrum Disorders in 505 participants. Completed in 30 July 2021.

Timeline

1 October 2020

Primary endpoint
30 July 2021

30 July 2021

Quick facts

Lead sponsor	Hanna Kahila
Status	Completed
Study type	OBSERVATIONAL
Enrollment	505
Start date	1 October 2020
Primary completion	30 July 2021
Estimated completion	30 July 2021
Sites	4 locations across Finland

Conditions studied

Fetal Alcohol Spectrum Disorders — all drugs for Fetal Alcohol Spectrum Disorders →

Sponsor

Hanna Kahila

Who can join

Eligibility, female only, with Fetal Alcohol Spectrum Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In order to find how many women continue using alcohol during their pregnancies the plan is to anonymously test routine urine samples collected during pregnancies for ethylglucuronide (ETG), a metabolite of ethanol that is detectable in urine up to several days after alcohol consumptions. Altogether 600 samples are taken in the prenatal care units and the prenatal care units dedicated for the alcohol and drug abusing mothers both in the Helsinki and Lahti areas. Test results are used to estimate and compare the prevalence of severe maternal drinking in the different populations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rapid urine screening for ethyl glucuronide from pregnant women as a tool for detecting prenatal alcohol exposure.
Jolma M, Koivu-Jolma M, Niemelä O, Autti-Rämö I, et al · · 2023 · cited 3× · PMID 37349673 · DOI 10.1186/s12884-023-05789-x

Verify or expand the search:

Other recruiting trials for Fetal Alcohol Spectrum Disorders

Currently open trials in the same condition.

NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
NCT06638463 — My Health Coach App RCT · NA · recruiting
NCT05960461 — Families Moving Forward (FMF) Connect Pro for Mental Health Providers · NA · recruiting
NCT04395196 — RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure · Phase 2 · recruiting
NCT05534568 — The Oklahoma Parent-Child Assistance Program · NA · recruiting

Other Hanna Kahila trials

Trials by the same sponsor.

NCT04918043 — Alcohol Use During Pregnancy in Finland According to Meconium Samples · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04571463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hanna Kahila
Last refreshed: 28 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04571463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing